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Syngenta – The Genome Giant?
No more “Mr. Nice Guy,” Syngenta makes a bid for multi-genome monopolies –
not just control of rice gene sequences but those of 40 plant species – as it plays
private games with public science and leads nanotech down on the farm.
ISSUE: Swiss gene giant Syngenta, the world’s largest agrochemical corporation and third largest seed
company (see tables) has applied for patents that could effectively allow the company to monopolize key
gene sequences that are vital for rice breeding as well as dozens of other plant species. Syngenta’s
enthusiasm for the rice genome stems from rice’s major genetic similarities (i.e., DNA or protein
sequences) to other species ranging from maize and wheat to bananas. (The genetic similarities are called
“homologies.”) While the Genome Giant “donates” rice germplasm and information to public researchers
with one hand, it is attempting to monopolize rice resources with the other. Governments, public sector
researchers and the United Nations must re-evaluate and reform their cozy connections to companies like
Syngenta.
IMPACT: At the close of 2004 – anointed the “International Year of Rice” by the United Nations –
researchers were just weeks away from completing a polished sequence of the rice genome, the DNA
blueprint of the crop that feeds half the world’s people – including information related to the control of
rice’s biological functions. Syngenta’s controversial and convoluted relationship with rice, poor farmers
and patents, including its sticky involvement with genetically modified Golden Rice and the Syngenta
Foundation’s embarrassing membership in the Consultative Group on International Agricultural Research
(CGIAR), could further hamper the United Nations’ Millennium Goal of halving the number of hungry
people by 2015 – especially the half that survives on rice.
POLICIES AND FORA: Syngenta should immediately withdraw its EPO patent claims and publicly
clarify its policy on genome sequence patenting and public access to genome data. In the meantime,
Syngenta should be removed from membership in CGIAR and excluded from UN fora. As a preemptive
action, ETC Group has written to the World Intellectual Property Organization (WIPO), the US Patent and
Trademark Office (USPTO) and the European Patent Office (EPO) urging them to reject Syngenta’s
sweeping patent applications related to the rice genome. When the Conference of the Parties to FAO’s
Genetic Resources Treaty meets in 2005, governments must ensure that genome sequence information is
deposited in public databases that guarantee free access but with strict prohibitions against intellectual
property on the use of information, germplasm and its parts and components. When the scientific
committee (SBSTTA) of the Convention on Biological Diversity (CBD) meets in Bangkok, February 7-11,
governments should examine the implications of “digital” genome patent claims on food security and
biodiversity, and take steps to prevent privatization. CGIAR, FAO and – most importantly, the UN in its
2005 review of the Millennium Development Goals – needs to re-establish the integrity of public
institutions, including governments, and the quality of governance vis-à-vis global corporations. Finally,
FAO and the UN must monitor and evaluate the impact of new technologies, including nano-scale
technologies, not only in food and agriculture but in every aspect of society and the economy.
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Introduction: DuPont has always been brighter
and Monsanto has always been “badder,” but in
2004 Syngenta has shown that it can get down and
dirty with the worst of them. At the end of
November 2004 at the Asia-Pacific Convention on
Food Sovereignty in Dhaka, Bangladesh, ETC
Group was asked point-blank, “Who is the
enemy?” by the farmers’ organizations present.
Expecting the almost ritual response, “Monsanto,”
the 600 delegates were treated instead to a litany
of Syngenta’s latest exploits. “If your concern is
food security,” the audience was told, “Syngenta
has crop genome patents pending that make
Monsanto’s outrageous soybean species patent
seem modest.1 If the issue is control of public
science, Syngenta is becoming omnipresent in
CGIAR and FAO. If your fear is technology
monopoly, Syngenta holds more patents on
Terminator seed technology than any other
company.2 And Syngenta is leading the pack in
bringing nanotechnology to crop chemicals.”
Here’s what Syngenta has been up to while we
were all watching Monsanto shoot itself in the
foot with biotech’s silver bullet…
Syngenta: Who’s Your Daddy?
Syngenta traces its roots to a long line of
multinational mergers and acquisitions:
1970 – Swiss chemical companies Ciba and
Geigy merge to form Ciba-Geigy.
1996 – Sandoz (Swiss) merges with Ciba-
Geigy (Swiss) to form Novartis.
1993 – ICI (British) spins off agrochemical,
seed and pharma interests to form Zeneca
(British).
1999 – Astra (Swedish pharmaceutical
company) merges with Zeneca to form
AstraZeneca (Swedish/British life sciences
company)
2000 – Novartis’ agrochemicals and seed
divisions and AstraZeneca’s agrochemical
business merge to form Syngenta.
Source
http://www.corporatewatch.org.uk/genetics/syng
enta.htm
Mr. Nice Guy…or just the Rice Guy? Tangled
Tales of the Rice Genome: Since 1997, both
public and private sector research groups
worldwide have been alternately competing and
collaborating to sequence the rice genome. The
front-runner consortium is the International Rice
Genome Sequencing Project (IRGSP), a network
of publicly funded laboratories in ten countries.
While the IGRSP focuses on the rice sub-species
japonica, the Beijing Genomics Institute (BGI) is
sequencing rice’s indica sub-species. Meanwhile,
in the private sector, Monsanto and Syngenta have
been avidly charting their own rice genome maps.
In early 2005, the international public sector rice
sequencers are inching to the finish line. Although
rice is only one of 1,182 registered genome
projects underway (as of mid-2004), it is
unquestionably the most relevant genome for
sustainable food security.3
Rice may not be a major commodity in world
trade, but it is cultivated in 113 countries and on
all continents except Antarctica.4 Developing
countries produce ninety-five percent of the
world’s rice production and rice feeds more of the
world’s people than any other crop. So it’s not
surprising that the rice genome is a focus for
public researchers – especially in Asia. But why
are multinational Gene Giants like Monsanto and
Syngenta competing and occasionally
collaborating in the rice race? Are the companies
taking the long view and looking for bucks at the
“bottom of the pyramid?” One reason is certain:
“rice is particularly attractive from a genomics
perspective,” explains Syngenta rice researcher
Stephen Goff, because “it has the smallest genome
of the important crop cereals [and is] a model for
the much larger genomes of maize and wheat.”5 In
other words, by sequencing the rice genome and
analyzing its genes and their functions,
researchers can uncover agronomic traits that
should pop up in many other – commercially (or
collectively) more important – species such as
maize, wheat and banana. The digital print-out of
a rice DNA sequence that codes for early-
maturity, for example, is very likely to turn up in
other crops. If a corporation can patent uses of the
sequence in rice, it can also lay claim to the same
sequence (homologous DNA) in dozens of other
species – or at least that’s what Syngenta hopes
patent examiners will believe! In the Gene Giant’s
food chain, rice is not an end but a means to multi-
genome monopoly.
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World’s Top 10 Agrochemical Firms
Company
2003
Agchem
Sales
US millions
1. Syngenta (Switzerland) $5,507
2. Bayer (Germany) $5,394
3. BASF (Germany) $3,569
4. Monsanto (US) $3,031
5. Dow (US) $3,008
6. DuPont (US) $2,024
7. Sumitomo Chemical (Japan) $1,141
8. MAI (Israel) $1,035
9. Nufarm (Australia) $801
10. Arysta (Japan) $711
Source: Agrow World Crop Protection News,
25 August 2004, PJB Publications Ltd.
Below, ETC Group examines the leading public
and private players and power struggles in the rice
race:
The International Rice Genome Sequencing
Project (IRGSP), a consortium of publicly
funded laboratories, led by rice genome
researchers in Tsukuba, Japan, was established in
1997 with the goal of producing a high quality,
map-based sequence of the rice genome using the
cultivar Nipponbare of the sub-species japonica –
the short-grain rice popular in Japan. Today, there
are 13 members of IRSGP in 10 countries.6
(Japan, USA, China, Taiwan, Korea, India,
Thailand, France, Brazil, and the UK.) The Project
adheres to a policy of immediate release of its
sequence data to the “public domain” (see box
below). IRGSP uses a slow and expensive
sequencing method known as “clone-by-clone,”
which provides the most precise and complete
sequence, with a goal of 99.99% accuracy across
the entire genome.
The Beijing Genomics Institute (BGI) is the
other major public sector effort to sequence the
rice genome. BGI’s focus is the rice sub-species
indica, which is grown in China and accounts for
most of the world’s rice. The Beijing researchers
are using the “whole genome shotgun” strategy, a
faster, but less accurate method than the “clone-
by-clone” technique.7
In April 2000 Monsanto, the world’s leading
purveyor of genetically modified seeds and traits,
made available its draft sequence of part of the
rice genome (using the “clone-by-clone” method)
to IRGSP. Monsanto, which had also sequenced
the Nipponbare strain, allowed members of
IRGSP to use the sequenced clones, on condition
that they not commercially exploit them.8
Less than one year later, in January 2001,
Syngenta and its partner Myriad Genetics (USA)
announced the completion of the draft sequence of
the japonica rice genome using the shotgun
method, but the company opted not to publish its
data. Noting that his company had finished
sequencing six months ahead of schedule, Adrian
Dubock, Syngenta’s Head of Ventures &
Licensing, told The Scientist, “we need a bit of
time to assess our own commercial interest…at
the moment we’ve a time advantage created with
commercial money and we’re looking for a
reward.”9 It was then that Syngenta’s lawyers
began actively seeking a reward – by filing
monopoly patent applications related to the rice
genome. (See below.) Adrian Dubock now serves
on the Golden Rice Humanitarian Board.
Later the same year, Syngenta announced a new
Technology Transfer Policy to facilitate the
South’s access to the company’s patented
technologies.10
In April 2002 the BGI (sequencing indica) and
Syngenta (sequencing japonica) simultaneously
published descriptions of their results in Science.
But while BGI placed its data in GenBank, the
standard repository for public genomic data,
Syngenta opted to restrict public access by placing
its data on the web site of its then-subsidiary
Torrey Mesa Research Institute (the California-
based lab that coordinated the sequencing).
Prominent academic researchers (including two
Nobel prize winners) protested the move. Echoing
the rationale of a year earlier, a Syngenta
spokesman told Science in 2002 that the company
believed it had “a significant commercial
advantage” and wasn’t ready to permit
unrestricted use of its data by its competitors.11
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The following month, responding to an outcry
from public scientists, and pressured by
Monsanto’s more media-savvy example, Syngenta
finally surrendered its rice data to the IRSGP
under an access agreement for participating
organizations.12
Top 10 Rice Producers 2003
(paddy production in metric tonnes)
1. China 166,000,000
2. India 133,513,000
3. Indonesia 51,849,200
4. Bangladesh 38,060,000
5. Viet Nam 34,605,400
6. Thailand 27,000,000
7. Myanmar 21,900,000
8. Philippines 13,171,087
9. Brazil 10,219,300
10. Japan 9,863,000
Source: FAO, 2004
Meanwhile, as scientists and Syngenta sparred
over the company’s undisclosed sequence
information, the company’s lawyers were filing
patents based on its findings.
The Humungous Homologue Heist: Recent
Syngenta Patent Applications In June 2002,
Syngenta applied for three patents based on its
rice genome research:
• WO03000904A2/3 relates to the
manipulation of “development and timing
of flower formation in plants and which
can be used to modulate flower
development, architecture and flowering
time.”
• WO03000905A2/3 discloses “a set of
genes the expression products of which are
up-regulated during the grain filling
process in rice and active in different
metabolic pathways involved in nutrient
partitioning. The invention also discloses
the use of said genes to modify the
compositional and nutritional
characteristics of the plant grain.”
• WO030007699A2/A3 provides
“polynucleotides encoding transcription
factors of cereals and in particular
rice...Also provided are recombinant
vectors, expression cassettes, host cells
and plants containing the polynucleotides.
Methods for using the polynucleotides to
alter resistance or tolerance of plants to
stress, alter biological pathways, and alter
gene expression are also provided.”
Dr. Paul Oldham of the ESRC Centre for
Economic and Social Aspects of Genomics at
Lancaster University (UK) has written a detailed
analysis of international patent application
WO03000904A2/3, which claims monopoly
control of DNA that regulates flowering
development, flower formation, whole plant
architecture and flower timing in rice – in up to
115 countries.13 According to Oldham, the scope
of the patent application is virtually limitless –
extending to flowering plants in general, including
those not yet classified by taxonomists! The 323-
page patent application extends to at least 23
major food crops under the International Treaty on
Plant Genetic Resources for Food and Agriculture
– the legally binding treaty governing the
conservation and exchange of vital crop
germplasm.14 Crop species protected by the Treaty
cannot be placed under intellectual property. If
Syngenta’s patents are approved, the fundamental
integrity of the Treaty is compromised.
Oldham warns that recent patent claims on DNA
sequences found across organisms may have
significant negative “anticommons” effects on the
future of agricultural research and innovation:
“The problem that emerges here is that if the
patent application is successful anyone using the
sequences, or ‘substantially similar’ or
‘homologous’ sequences for trait selection,
identifying varieties, and plant breeding may run
the risk of patent infringement. This extends to the
use of the sequences within a primer and computer
readable [digital] medium.”15 “Does this imply,”
asks Oldham, “that public and private research
initiatives may be required to enter into
agreements with patent holders [Syngenta] for the
use of  the DNA sequences, or ‘homologous’ or
‘substantially-similar’ sequences, or risk potential
litigation?”16
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Syngenta’s pending patents may be accepted,
rejected or amended by the European Patent
Office any day now. It is customary for corporate
patent lawyers to reach for the moon when they
craft their claims, of course, but Syngenta’s claims
are a true reflection of its willingness to
monopolize the genome of one of the world’s
most critical food crops – and much more. Patent
offices increasingly view the Gene Giants as their
“customers” rather than seeing themselves as
defenders of the public good.   
If Syngenta has no intention to monopolize rice
or other crop genomes, the company should
immediately withdraw its EPO patent claims and
publicly clarify its policy on genome sequence
patenting and public access to genome data.
Regardless of its patent posture, Syngenta should
be removed from membership in CGIAR. Until
Syngenta abandons its claims and corrects its
public domain policies, it should be denied its
observer status in UN fora.
A Firm’s Foundation? CGIAR as Syngenta’s
Southern Exposure: In late October 2002, four
short months after Syngenta filed its rice DNA
sequence patents, the Consultative Group on
International Agricultural Research (CGIAR) – a
network of 15 research centres whose goal is to
generate “global public goods that are available to
all” – welcomed four new members: Israel,
Malaysia, Morocco and the Syngenta Foundation.
While CGIAR membership is open to private
foundations that support the CGIAR’s mission as
well as to governments, the Syngenta Foundation
has a character distinguishing it from the three
other foundation members of CGIAR (Ford,
Kellogg and Rockefeller). Most obviously, none
of the other foundations are linked to transnational
enterprises in the seed and agrochemical business.
According to the Syngenta Foundation web site,
“the CGIAR welcomed the Foundation’s
membership as marking ‘an important new
direction in addressing hunger and poverty around
the globe.’”17 New direction indeed. Five men
serve on the Syngenta Foundation’s Board. Of the
five, two also serve on the Board of Syngenta:
Heinz Imhof is President of the Syngenta
Foundation as well as Chairman of the Board of
Syngenta. Pierre Landolt is also on both Boards
(and on the Board of Novartis, the Basel-based
pharmaceutical giant and former parent of
Syngenta). (Andrew Bennett, the Foundation’s
Executive Director, is a long-time CGIAR insider
as former chair of the Group’s Oversight
Committee and as former director of rural
livelihoods and environment and chief natural
resources adviser at the UK government’s
Department for International Development.
Christian Bonte-Friedman, another Foundation
board member, is even more of an insider, having
been Director General of a CGIAR centre
[ISNAR, now defunct] and an Assistant Director
General of FAO.)18
According to the Syngenta Company’s articles of
incorporation, “the Board of Directors shall
consist of a maximum of twelve members who
shall be shareholders.”19 In addition, the Chairman
of the Board “shares responsibility for the
strategic direction of Syngenta with the Chief
Executive Officer (CEO)... [and] represents,
jointly with the CEO, the interests of the
Company as a whole...”20  This means that at least
two board members of the Syngenta Foundation
are shareholders of the Syngenta Company and
that the Foundation’s President also happens to be
responsible for the “strategic direction” of the
Company. And it means that the Company can
heavily influence the activities of the Foundation.
The Foundation’s goals and the Corporation’s
goals are not the greatest concern. The real
concern is that the goals and work of CGIAR, as a
public sector network, are being influenced by
Syngenta’s private sector agenda. For example,
when CGIAR finally decided to examine the issue
of GM contamination in September 2004,
Syngenta – the Company – was invited to attend
and give its views. Farmers’ organizations were
not invited.21 Why has CGIAR allowed Syngenta
to play a role in public sector international
agricultural governance?
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Necrofieldiacs, or FAO’s Pests? Syngenta is only the most prominent among many multinational seed,
biotech and agrochemical companies becoming common fixtures in the UN Food and Agriculture
Organization’s corridors in Rome. Some attribute their increasingly pervasive presence to the UN
Secretary-General’s Global Compact – the UN’s new strategy of partnering with multinational corporations
as part of the Millennium Development Goals. While Syngenta isn’t a card-carrying member of the Global
Compact (although its former parent, Novartis is), the genome giant is a member of CropLife International,
the Brussels-based global pesticide trade association better known to its environmental critics as the
“Necrofieldiac” of organic farming. The growing influence of CropLife International, and of Syngenta in
particular, has resurrected concerns that FAO’s past close collusion with multinational agribusiness is
returning. Syngenta’s CEO is currently the president of CropLife.
In the late 1960s, A.H. Boerma, a former Dutch Minister of Agriculture and consultant to Shell Oil (then
heavily invested in agrochemicals) became Director-General of FAO and quickly threw his support behind
the Industry Cooperative Programme (ICP). The ICP was an undisguised lobby group for agribusiness
whose staff were ensconced directly within FAO headquarters. During Boerma’s reign, the ICP dominated
FAO’s policies and publications related to the use of crop chemicals and also worked closely with the
international centres that eventually formed the CGIAR. ICP officials led and directed national advisory
teams, wrote chemical user handbooks, and generally promoted the concepts of industrial agriculture
throughout the South under the FAO banner.22 However, when Edouard Saoma, an FAO insider, unseated
Boerma in 1976, he joined forces with Sweden and other sympathetic governments to oust the ICP on the
grounds that it was compromising good governance. Ah, the good old days!
Within a year, however, the ICP was transformed into the ICD (Industry Council for Development) under
the protection of the UN Development Program and headquartered at UN Plaza in New York.
Multinational encroachment in agriculture surfaced again in the preparations for the World Food Summit of
1996. At that time, the fledgling new Director-General of FAO, Jacques Diouf, desperate to finance the
expensive Summit, penned a letter to major food and agricultural corporations inviting their CEOs to
participate in the Summit as his personal guests. In return for a $1 million contribution, the Director-
General offered to give the corporations access to all aspects of the Food Summit and to grant them priority
access to directly influence any follow-up policies and programmes in their fields of interest. When CSOs
got wind of the proposal, the Director-General withdrew his offer.
Thus, when FAO released its 2004 State of the World’s Food and Agriculture (Sofa) report favorable to
agricultural biotechnology, civil society organizations were understandably alarmed. Since then, the
growing presence of Syngenta and CropLife International in the FAO headquarters and meetings has
caused CSO concerns to escalate.
The Golden Rice Guy: Tarnished Transgenes
and Tainted Trust: For those who have followed
the fractious biotech debate, Syngenta and Golden
Rice are nearly synonymous. Golden Rice refers
to the genetically modified, beta carotene-enriched
rice that industry heralds as the biotech solution to
Vitamin A deficiency plaguing millions of poor
people in the South. It’s the biotech industry’s
favourite ‘proof of concept’ that GM crops could
benefit poor people – in other words, it’s powerful
PR. Steve Linscombe, senior rice breeder at
Louisiana State University (LSU, USA) where
Golden Rice was grown in field trials this
summer, explains it this way: “We look at
[Golden Rice] as a good mechanism for informing
the public that genetic engineering does have a lot
of positive benefits.”23 ETC Group and other
critics note that is not yet known whether Golden
Rice is a safe, effective or appropriate technology;
there are safer, cheaper and less controversial
methods for addressing Vitamin A deficiencies.
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On the eve of World Food Day 2004, Syngenta
generated headlines by announcing it would
donate new Golden Rice seed and lines to poor
farmers in the developing world via the Golden
Rice Humanitarian Board and stated that “the
company has no commercial interest in the
Golden Rice project.”24 When asked for
clarification on this point, a spokesperson for
Syngenta explained to ETC Group that the
company will retain rights but, “in the long view”
has “no plans” to commercialise Golden Rice.25
But Syngenta’s self-presentation as magnanimous
steward of Golden Rice is misleading. In May
2000, millions of dollars and 10 years worth of
publicly funded research on Golden Rice was
surrendered to multinational Gene Giant
AstraZeneca (now Syngenta) because the public
sector researchers developing it were paralyzed in
the face of an estimated 70-105 patents which they
believed blocked commercial release of Golden
Rice technology. In reality, the patents were not
insurmountable obstacles for poor countries.26
Assuming the position of owner, the company
promptly announced that it would donate “license
free” rights for poor farmers in the South – a move
that generated substantial publicity and
considerable controversy.27
To date, Golden Rice has not been
commercialized anywhere in the world, but it was
field-tested for the first time in 2004 in Louisiana
on a test plot approximately 40m x 10m.
September’s harvest is currently being tested for
Vitamin A content and the results are expected to
be published within a year.28 According to
Syngenta, more field trials will be conducted in
Asia in 2005.29
Meanwhile, a Golden Rice Humanitarian Board
has been established to steward the project, and to
foster the use of GM rice for humanitarian
purposes in poor countries. The Board’s
responsibilities include overseeing biosafety and
socio-economic assessments, supporting
deregulation and mediating information.30  In
addition to the two “inventors” of Golden Rice,
Ingo Potrykus and Peter Beyer, the Board includes
representatives from CGIAR Centres (IRRI,
IFPRI), national government agencies (USDA),
private foundations (Rockefeller), universities
(Cornell and Swiss Federal Institute of
Technology) and one private corporation
(Syngenta). Syngenta’s representative on the
Board is Adrian Dubock, Head of Ventures &
Licensing.
One of the groups represented on the
Humanitarian Board is IRRI, the International
Rice Research Institute, one of the CGIAR
centres. IRRI has established a “Golden Rice
Network” to facilitate its development and
distribution. Dr. Gerard Barry, former Director of
Research Product and Technology Cooperation,
Monsanto (among other positions held at
Monsanto), became coordinator of the Golden
Rice Network at IRRI in late 2003. His title is
Deputy Director General for Partnerships.
Syngenta’s 2004 Seed Company
Acquisitions
• Advanta BV (including Garst maize and
soybean)
• Garwood Seed
• Golden Seed Co., LLC
• Golden Seed Co. Inc.
• J.C. Robinson Seeds, Inc.
• Sommer Bros. Seed Co.
• Thorp Seed Co.,
• Golden Harvest Seeds, Inc.
• maize breeding material from CHS
Research
With these acquisitions Syngenta increases
its North American market share to
approximately 15% in maize and 13% in
soybeans.31
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Public domain…or dominating the public?
In a world of run-away privatization, the concept of “public domain” is being perverted. Unfortunately,
depositing genomic information in public databases does not guarantee that it won’t be privatized.
In theory, public domain germplasm and information cannot be subject to IP claims per se, because they
are already “public”— existing as prior art, and therefore not “new.” Gene Giants like Syngenta state that
“unaltered genetic material in its natural environment is not patentable.”32 But there are giant loopholes that
render these principles meaningless. Once isolated, modified, purified, altered or recombined, the “raw”
material becomes fair game for monopoly patent claims. The following examples illustrate how so-called
“public domain” resources can be turned into patentable, private commodities:
J. Craig Venter, the controversial and flamboyant genomics mogul, is leading a US-government funded
ocean expedition to collect microbial diversity from marine and terrestrial environments worldwide.33
Microbial samples collected by the expedition are shipped to Venter’s laboratory in Maryland (USA) where
they are de-coded by a fleet of sequencing machines that operate around the clock. Venter’s non-profit
Institute for Biological Energy Alternatives pledges not to patent the raw microbes it collects, a pledge that
aims to silence critics and defenders of national sovereignty – while leaving the back-door open to
monopoly patent claims. Modified microbes or new life forms engineered from collected microbes, as well
as products or derivatives based on genomic information, can be patented and privatized. Furthermore, only
a handful of institutions have the capacity to handle the genomic information and the high-tech, costly tools
required for its interpretation. And many of these tools are themselves proprietary technologies.
The legally-binding International Treaty on Plant Genetic Resources seeks to insure international
cooperation and open exchange of “any genetic material of plant origin of actual or potential value for food
and agriculture,” most of which was developed, improved and exchanged by farmers over 10,000 years.
The Treaty applies to over 64 major crops and forages. Although the spirit of the Treaty is to safeguard
Farmers’ Rights and to prohibit intellectual property claims on plant genetic resources covered under its
Multilateral System, ambiguous clauses on intellectual property threaten to betray farmers and the public
interest: “Recipients (of material taken from the covered crops) shall not claim any intellectual property or
other rights that limit the facilitated access to the plant genetic resources for food and agriculture, or their
genetic parts or components, in the form received from the Multilateral System.” The clause, “in the form
received,” means that you can’t slap a patent on exchanged seed or even its genes or fragments – but the
door is ajar to intellectual property claims once breeders change the original material – effectively making
the Multilateral System a “feedstock” for genetic material that breeders can modify to gain exclusive
monopoly. But how much breeding work is required before something is considered novel and therefore
patentable? A recent CGIAR publication provides a “handbook” on how and under what conditions
intellectual property can be claimed on derivative material included under the Multilateral System.34
Does putting information (genes, seeds, human DNA, etc.) in the public domain facilitate piracy? In the
context of today’s intellectual property regimes, the answer is yes. There are few mechanisms to prevent
individuals and enterprises from seeking to privatize collective public resources, and many rewards for
doing so. Does this imply that it would be better to keep information out of the public domain? No. First
and foremost, patents on nature should be illegal. Second, governments and public sector bodies must re-
evaluate and strengthen public domain resources and the collective rights of innovators.
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Biotech’s Gene Giants
Gene Giant
Agrochemical
Sales 2003
Seed Sales
 2003
Syngenta $5,507 $1,071
Monsanto $3,031 $1,879
Dupont $2,024 $2,240
Source: ETC Group
How Small is Syngenta? Nanotech Down on the
Farm: While Syngenta’s seed sales were over a
billion dollars in 2003, the bulk of its revenue
came from sales of its agrochemicals, which
exceeded seed sales five-fold ($5.5 billion).
Syngenta, like other Gene Giants, are now
researching and, in some cases, selling
agrochemicals containing nano-scale active
ingredients, that is, particles on the scale of atoms
and molecules. Nano-scale materials are just
beginning to get attention from scientists and
regulators because they appear to exhibit different
toxicity from the same materials on larger scales.
Currently, no government regulatory system in the
world is prepared to address the potential health
and environmental impacts of manufactured
nanoparticles. (See ETC Group report, “Down on
the Farm,” available at www.etcgroup.org.)
Syngenta already sells pesticide products
formulated as emulsions containing nano-scale
droplets.  The company says that the particle sizes
are about 250 times smaller than typical pesticide
particles. According to Syngenta, the active
ingredients are absorbed into the plant’s system
and cannot be washed off by rain or irrigation.35
Nano-scale pesticides can also be encapsulated –
packaged within a kind of tiny “envelope” or
“shell” – and Syngenta is researching nano-
encapsulated pesticides, in order to control the
conditions under which the chemicals are
released.36 Will nano-encapsulated pesticides pose
greater threats to human health and safety, and the
environment? Will nano-scale pesticides be
smuggled into the food chain more readily? At
this point, nobody knows the answers to these
questions.
Recommendations: All of today’s Gene Giants
challenged the infamous soybean species patent
granted by the European Patent Office to
Agracetus in 1994. Then Monsanto had an
epiphany and decided that monopoly control of a
major food crop was a great idea and perfectly
ethical. Monsanto bought Agracetus acquiring
control of the patent and defending it in court.37
Twelve years later, ETC Group and Syngenta are
still challenging the species patent. Why should
we be surprised that one of the Gene Giants is
now going after multi-genome monopolies? The
rise of genomics allows claims across species,
genera and classes.38
If Syngenta has no intention to monopolize rice or
other crop genomes, the company should
immediately withdraw its EPO/WIPO patent
claims and publicly clarify its policy on genome
sequence patenting and public access to genome
data. Regardless of its patent posture, Syngenta
should be removed from membership in CGIAR.
Until Syngenta abandons its claims and corrects
its public domain policies, it should be denied its
observer status in UN fora.
ETC Group has preemptively written to WIPO,
EPO and USPTO urging them to immediately
reject Syngenta’s sweeping multi-genome patent
applications. Because of the implications for the
FAO Treaty on Plant Genetic Resources for Food
and Agriculture, public research, and food
sovereignty, ETC Group has also written to FAO
and CGIAR urging both organizations to demand
the rejection of the Syngenta claims.   
When the Conference of the Parties to FAO’s
Genetic Resources Treaty meets in 2005,
governments must ensure that genome sequence
information is deposited in public databases
without restrictions but with strict prohibitions
against intellectual property on the use of
information, germplasm and its parts and
components. Civil society and UN agencies
should also examine public domain issues
including public databases and repositories to
ensure that the public’s interests are truly being
served and that intellectual property or other
monopolistic claims are not allowed.
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When the scientific committee (SBSTTA) of the
Convention on Biological Diversity (CBD) meets
in Bangkok, February 7-1l, governments should
examine the implications of “digital” genome
patent claims for food security and biodiversity.
CGIAR, FAO and – most importantly, the UN in
its 2005 review of the Millennium Development
Goals – needs to re-establish the integrity of
governments and the quality of governance vis-à-
vis global corporations.
Finally, FAO and the UN must monitor and
evaluate the impact of new nano-scale
technologies not only in food and agriculture but
in every aspect of society and the economy.
Rice: The Events of Sequencing
1997 The International Rice Genome Sequencing Project (IRGSP), a consortium of publicly funded
laboratories, led by the Rice Genome Research Program in Tsukuba, Japan, is established.
April 2000 Monsanto makes available to IRGSP a draft sequence of part of the rice genome using the
“clone-by-clone” method.
May 2000 Beijing Genomics Institute (BGI) sets out to sequence the genome of the rice sub-species
indica.
May 2000 The Swiss and German researchers who developed Golden Rice announce they cannot navigate
the tangle of patent licenses needed to get Vitamin A rice to farmers and opt to surrender their
research (the product of $9 million in public funding) to AstraZeneca.
July 2000 European Commission clears the merger of the agrochemicals/seed divisions of Novartis and
AstraZeneca to create Syngenta
Jan. 2001 Syngenta announces that it has completed the sequencing of the japonica rice genome, but does
not publish the data.
April 2002 BGI (sequencing indica) and Syngenta (sequencing japonica) publish descriptions of their
sequencing results in Science. BGI deposits data in GenBank; Syngenta does not.
June 2002 Syngenta files for three patents based on its rice genome research.
July 2002 Syngenta announces that it will share its draft sequence with two member laboratories of IRGSP
and agrees “to allow its data to be inserted into GenBank as part of any finished sequence
submitted by [IRGSP],” though public access to its genome data remains restricted through the
TMRI web site.39
Oct. 2002 Syngenta Foundation for Sustainable Agriculture becomes a member of the CGIAR.
Dec. 2002 The UN declares that 2004 will be the “International Year of Rice.”
Dec. 2002 IRGSP announces the completion of a high quality draft sequence of the rice genome.
Sept. 2004 The first Golden Rice field trials are harvested in the USA at Louisiana State University’s
AgCenter’s Rice Research Station.
Oct. 2004 Syngenta announces its “donation” of Golden Rice seeds and lines to the Golden Rice
Humanitarian Board.
Dec. 2004 IRGSP notes that the formal announcement of the completion of the rice genome is imminent.
ETC Group Communiqué, Issue # 86
www.etcgroup.org
11
World’s Top 10 Seed Corporations
Company 2003 Seed
Sales
US millions
2002 Seed
Sales
US millions
1. Dupont (Pioneer) US $2,24040 $2,000
2. Monsanto (US) $1,879 $1,600
3. Syngenta (Switzerland) $1,071 $937
4. KWS AG (Germany) $52941 $391
5. Seminis (US) $477 $453
-  Advanta (Netherlands) Sold to
Syngenta
$435
6. Groupe Limagrain (Vilmorin
Clause) France
$497 $433
7. Sakata (Japan) $395 $376
8. Delta & Pine Land  (US) $315 $258
9. Bayer Crop Science
(Germany)
$31142 $250
10. Dow (US) $20443 $200
                                                 
1See ETC Group’s news release, “Patently Wrong!” May 7, 2003, available on the Internet at
http://www.etcgroup.org/article.asp?newsid=398
2For a list of Syngenta’s Terminator patents, see: http://www.etcgroup.org/article.asp?newsid=389
Syngenta’s official position on genetic seed sterilization states: “Syngenta and its predecessor companies have a long-
standing policy not to use the so-called ‘terminator’ technology to prevent seed germination.” The Syngenta position
statement is available on the company web site: http://www.syngenta.com/en/social_responsibility/position.aspx
3 Paul Oldham, “Global Status and Trends in Intellectual Property Claims: Genomics, Proteomics and Biotechnology,”
submission to the Executive Secretary of the Convention on Biological Diversity, ESRC Centre for Economic and Social
Aspects of Genomics (UK), October 2004, p. 4. On the Internet: http://www.cesagen.lancs.ac.uk/docs/genomics-final.doc
4 Ben Rosenberg, “2004 is the International Year of Rice,” Geneflow, IPGRI, p. 37.
5 Bruce Lieberman, “S.D. team maps rice strain's gene code,” n. d., SignOnSandiego.com
6 IRGSP website:  http://rgp.dna.affrc.go.jp/IRGSP
7 BGI web site and Eliot Marshall, “A Deal for the Rice Genome,” Science, Vol. 296, Issue 5565, 34, April 5, 2002.
8 Proceedings of the 20th Session of the International Rice Commission, Bangkok, Thailand, 23-26 July 2002.
9 Robert Walgate, “Syngenta claims ownership of rice – but will give data away,” The Scientist, February 1, 2001.
The Syngenta Foundation lists three current projects on its web site. www.syngentafoundation.org : millet and sorghum
improvement in Mali, land and resource management in Eritrea and insect resistant maize seeds in Kenya. The development
/ distribution of Golden Rice is not a project of the Syngenta Foundation.
10 Oldham, p. 38.
11 Eliot Marshall, “A Deal for the Rice Genome,” Science, Vol. 296, Issue 5565, 34, April 5, 2002.
12 Oldham, p. 38-39. For further details, see: “IRGSP-Syngenta Rice Genome Announcement Release,” 23 May 2002. On
the Internet: http://www.nias.affrc.go.jp/pressrelease/2002/20020523/announcement.html
13 Oldham, p. 47.
14 According to Oldham, Syngenta’s (WO03000904) international patent application claims “…any plant species” can be
transformed, followed by a list of 40 individual species, (i.e. maize, banana, sorghum, millet etc), all genera and species of
duckweed (Lemna) including those as yet unknown, 6 genera of vegetables, 10 ornamentals, 11 conifers (i.e. pines), 3
cedars, 11 leguminous plants (beans, peas), +8 legumes, 6 forage/turf grasses, 55 other plants, including 20 members of the
Brassica complex (i.e. broccoli, cabbage), and 28 specific ornamental plants. Oldham, p. 39.
15 Ibid., p. 46.
16 Ibid., p. 47.
17 http://www.syngentafoundation.com/partnerships.htm
18 The other Syngenta Foundation Board member is Klaus M. Leisinger, who is also Executive Director and President of the
Novartis Foundation for Sustainable Development.
19 See http://www.syngenta.com/en/downloads/syngenta-statuten-e.pdf
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20 Ibid.
21 See ETC Group, News Release, “Taking Care of Business: The CGIAR and GM Contamination,” August 27, 2004.
22 Food First, Circle of poison - Pesticides and People in a Hungry World, 1981, chapter 7, available on the Internet at
http://payson.tulane.edu:8085/cgi-bin/gw?e=t1c11misc-envl-1-T.1.B.73.1-500-50-00e&q=&d=T.1.B.73.10&a=t
23 “Golden staple could help solve problem of malnutrition,” The Lafayette Daily Advertiser, October 21, 2004, on the
Internet: http://www.theadvertiser.com/news/html/24894A55-326C-4A17-89CD-DA9DBDA336C0.shtml (Bruce Shultz of
the LSU AgCenter contributed to this story.)
24 See Syngenta news release at http://www.syngenta.com/en/media/article.aspx?article_id=449
25 Phone conversation with Anne Burt of Syngenta, December 15, 2004.
26 See RAFI (ETC Group) Communiqué, “Golden Rice and Trojan Trade Reps,” October 2000. On the Internet:
www.etcgroup.org
27 Ibid.
28 Email communication with Dr. Steve Linscombe, December 16, 2004.
29 See http://www.syngenta.com/en/popups/viewB.html
30 See http://www.fao.org/documents/show_cdr.asp?url_file=/DOCREP/006/Y4751E/y4751e06.htm
31 Syngenta News Release, “EU approves acquisition of Advanta by Syngenta,” Basel, August 17, 2004.
32 See, for example, Syngenta’s official position on intellectual property, available on the company’s web site:
http://www.syngenta.com/en/social_responsibility/position.aspx
33 For background, please see ETC Group, “Playing God in the Galapagos,” Communiqué, March/April 2004. Venter’s
Institute for Genomic Research is one of the publicly-funded institutions participating in the IRGSP.
34 Fowler, Cary, “The Status of Public and Proprietary Germplasm and Information: an Assessment of Recent
Developments at FAO.” In IP Today, No.7-2003, Ithaca, NY, USA. See also: “Fowler, Cary; Engels, Jan and Frison,
Emile, “The Question of Derivatives: Promoting use and ensuring availability of non-proprietary plant  genetic resources”
in Issues in Genetic Resources No. 12 -September 2004, IPGRI, Rome, Italy”
35 See Syngenta’s Banner MAXX brochure on the Internet:
http://www.engageagro.com/media/pdf/brochure/bannermaxx_brochure_english.pdf
36 Syngenta’s patent, WO0194001A2, relates to nano and micron size capsules for agrochemicals.
37 See ETC Group’s news release, “Patently Wrong!” May 7, 2003, available on the Internet at
http://www.etcgroup.org/article.asp?newsid=398
38 Oldham, p. 47.
39 Nicole Johnston, “Rice Genome Rising,” The Scientist, March 1, 2004.
40 DuPont: 2003 Data Book, www.dupont.com
41 http://www.kws.de/global/show_document.asp?id=aaaaaaaaaacikrn  (converted from €443.7 million)
42 This figure also includes seed treatments. Phone Conversation with Norbert Lemken, Bayer Cropscience, Germany,
December 21, 2004. (275 million Euros = 311 US dollars).
43 Estimate provided by Dow AgroSciences.
